Clinical application of a novel CD45-negative cell sorting in cytogenetic detection of multiple myeloma

Guo CHEN; Yunjing ZENG; Ping WANG; Xiaojuan DENG; Ying XIANG; Yunlong LI; Xiangui PENG; Li GAO; Xi ZHANG

doi:10.16016/j.1000-5404.202003335

您当前的位置：

首页 >

文章列表页 >

Clinical application of a novel CD45-negative cell sorting in cytogenetic detection of multiple myeloma

更新时间：2026-01-09

- Clinical application of a novel CD45-negative cell sorting in cytogenetic detection of multiple myeloma
- Journal of Third Military Medical University Vol. 42, Issue 17, Pages: 1681-1686(2020)
- 作者机构：
- 作者简介：
- 基金信息：
  
  the General Project of Technology Innovation and Application Demonstration of Chongqing(CSTC2018jscx-msybX0045)
- DOI：10.16016/j.1000-5404.202003335
  CLC：
- Received：26 March 2020，
  
  Published：15 September 2020
- 稿件说明：
移动端阅览
Guo CHEN, Yunjing ZENG, Ping WANG, et al. Clinical application of a novel CD45-negative cell sorting in cytogenetic detection of multiple myeloma[J]. Journal of Third Military Medical University, 2020, 42(17): 1681-1686.
DOI：

Guo CHEN, Yunjing ZENG, Ping WANG, et al. Clinical application of a novel CD45-negative cell sorting in cytogenetic detection of multiple myeloma[J]. Journal of Third Military Medical University, 2020, 42(17): 1681-1686. DOI： 10.16016/j.1000-5404.202003335.

摘要

Abstract

Objective

To explore the clinical value of a novel CD45-negative cell sorting technology in sorting and enriching tumor plasma cells in multiple myeloma (MM).

Methods

A total of 60 newly diagnosed MM patients from 3 hospitals in Chongqing from July 2018 to December 2019 were recruited in this study. Bone marrow samples of 3~4 mL were taken from each patient and divided into 2 parts. One part (direct detection group) was directly detected by flow cytometry and FISH

and the other part (CD45 sorting group) was subjected to the novel CD45-negative cell sorting

followed by flow cytometry and FISH. The proportion of plasma cells in bone marrow

detection rate of cytogenetic abnormalities and risk stratification were compared in every patient before and after sorting.

Results

The proportion of plasma cells in bone marrow samples was (14.5±13.8)% and (51.5±30.3)%

respectively

in the direct detection group and CD45 sorting group

with that of the latter group 7.69 times higher than that of the former group (

＜0.001). Direct FISH indicated 17 cases of cytogenetic abnormality

while FISH after CD45 sorting found 39 patients having cytogenetic abnormalities (

＜0.001). The positive rates of IgH rearrangement

13q14 deletion

1q21 amplification and 17p deletion were all increased significantly after sorting. According to mSMRAT3.0 standard

onl

y 28.3% of the patients were identified at high risk before sorting

but the number was increased significantly after sorting (accounting for 53.3%

=0.002).

Conclusion

The new CD45 negative cell sorting technology is simple and easy to operate

and can improve the detection rate of cytogenetic abnormalities and accurately carry out risk stratification for guiding treatment in MM patients. Thus

this technology is worthy of promotion in primary hospitals.

关键词

Keywords

references

SONNEVELD P AVET-LOISEAU H LONIAL S Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Blood 2016 127 24 2955 2962 10.1182/blood-2016-01-631200 SONNEVELD P, AVET-LOISEAU H, LONIAL S, et al . Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group[J ] . Blood, 2016, 127(24): 2955-2962. DOI:10.1182/blood-2016-01-631200.

安刚李承文李倩免疫磁珠分选对荧光原位杂交检测多发性骨髓瘤细胞遗传学异常的影响中国实验血液学杂志 2011 19 1 54 58 安刚, 李承文, 李倩, 等. 免疫磁珠分选对荧光原位杂交检测多发性骨髓瘤细胞遗传学异常的影响[J]. 中国实验血液学杂志, 2011, 19(1): 54-58.

AN G LI C W LI Q Influence of immunomagnetic sorting on detecting genetic aberration of multiple myeloma cells by interphase fluorescence in situ hybridization J Exp Hematol 2011 19 1 54 58 AN G, LI C W, LI Q, et al . Influence of immunomagnetic sorting on detecting genetic aberration of multiple myeloma cells by interphase fluorescence in situ hybridization[J ] . J Exp Hematol, 2011, 19(1): 54-58.

FONSECA R BERGSAGEL P L DRACH J International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 2009 23 12 2210 2221 10.1038/leu.2009.174 FONSECA R, BERGSAGEL P L, DRACH J, et al . International Myeloma Working Group molecular classification of multiple myeloma: spotlight r eview[J ] . Leukemia, 2009, 23(12): 2210-2221. DOI:10.1038/leu.2009.174.

GONSALVES W I TIMM M M RAJKUMAR S V Influence of immunomagnetic sorting on detecting genetic aberration of multiple myeloma cells by interphase fluorescence in situ hybridization J Exp Hematol 2016 44 32 39 10.1016/j.leukres.2016.03.003. GONSALVES W I, TIMM M M, RAJKUMAR S V, et al . The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma[J ] . Leuk Res, 2016, 44: 32-39. DOI:10.1016/j.leukres.2016.03.003.

KALLERGI G POLITAKI E ALKAHTANI S Evaluation of isolation methods for circulating tumor cells (CTCs) Cell Physiol Biochem 2016 40 3/4 411 419 10.1159/000452556 KALLERGI G, POLITAKI E, ALKAHTANI S, et al . Evaluation of isolation methods for circulating tumor cells (CTCs)[J ] . Cell Physiol Biochem, 2016, 40(3/4): 411-419. DOI:10.1159/ 000452556.

WANG G K BENASUTTI H JONES J F Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles Colloids Surf B Biointerfaces 2018 161 200 209 10.1016/j.colsurfb.2017.10.060 WANG G K, BENASUTTI H, JONES J F, et al . Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles[J ] . Colloids Surf B Biointerfaces, 2018, 161: 200-209. DOI:10.1016/j.colsurfb.2017.10.060.

D’AGOSTINO M BERTAMINI L OLIVA S Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies Cancers (Basel) 2019 11 12 10.3390/cancers11122015 D’AGOSTINO M, BERTAMINI L, OLIVA S, et al . Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies[J ] . Cancers (Basel), 2019, 11(12): E2015. DOI:10.3390/cancers11122015.

MINA R BONELLO F PETRUCCI M T Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies Haematologica 2020 10.3324/haematol.2019.243428 MINA R, BONELLO F, PETRUCCI M T, et al . Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies[J ] . Haematologica, 2020. . DOI:10.3324/haematol.2019.243428.

LI X Z CHEN W M WU Y 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China Oncologist 2019 24 11 10.1634/theoncologist.2019-0132 LI X Z, CHEN W M, WU Y, et al . 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China[J ] . Oncologist, 2019, 24(11): e1132-e1140. DOI:10.1634/theoncologist.2019-0132.

FLORES-MONTERO J DE TUTE R PAIVA B Immunophenotype of normal vs Toward antibody panel specifications for MRD detection in multiple myeloma 2016 90 1 61 72 10.1002/cyto.b.21265 FLORES-MONTERO J, DE TUTE R, PAIVA B, et al . Immunophenotype of normal vs . myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma[J ] . Cytometry B Clin Cytom, 2016, 90(1): 61-72. DOI:10.1002/cyto.b.21265.

高露刘清师岩应用 CD138 免疫磁珠分选结合荧光原位杂交技术检测多发性骨髓瘤细胞遗传学异常中国实验血液学杂志 2017 25 3 807 812 高露, 刘清, 师岩, 等. 应用 CD138 免疫磁珠分选结合荧光原位杂交技术检测多发性骨髓瘤细胞遗传学异常[J]. 中国实验血液学杂志, 2017, 25(3): 807-812. DOI：10.7534/j.issn.1009-2137.2017.03.031.

GAO L LIU Q SHI Y Immunophenotype of normal vs Toward antibody panel specifications for MRD detection in multiple myeloma 2017 25 3 807 812 10.7534/j.issn.1009-2137.2017.03.031. et al . Application of CD138 immunomagnetic sorting myeloma cells combined with fluorescence in situ hybridization for detecting cytogenetic abnormalities of multiple myeloma [J ] . J Exp Hematol, 2017, 25(3): 807-812. DOI：10.7534/j.issn.1009-2137.2017.03.031.

LAI Y Y HUANG X J CAI Z Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China Chin Med J 2012 125 15 2663 2670 LAI Y Y, HUANG X J, CAI Z, et al . Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China[J ] . Chin Med J, 2012, 125(15): 2663-2670.

吴昊张慧何海燕 532 例多发性骨髓瘤患者细胞遗传学异常及对预后的影响中华血液学杂志 2017 38 9 739 743 10.3760/cma.j.issn.0253-2727.2017.09.002. 吴昊, 张慧, 何海燕, 等. 532 例多发性骨髓瘤患者细胞遗传学异常及对预后的影响[J]. 中华血液学杂志, 2017, 38(9):739-743. DOI：10.3760/cma.j.issn.0253-2727.2017.09.002.

WU H ZHANG H HE H Y Immunophenotype of normal vs Toward antibody panel specifications for MRD detection in multiple myeloma 2005 19 8 1466 1470 10.3760/cma.j.issn.0253-2727.2017.09.002. WU H, ZHANG H, HE H Y, et al . Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma[J ] . Chin J Hematol, 2017, 38(9):739-743. DOI：10.3760/cma.j.issn.0253-2727.2017.09.002.

KUMAR S RAJKUMAR S V KIMLINGER T CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations Leukemia 2005 19 8 1466 1470 10.1038/sj.leu.2403823. KUMAR S, RAJKUMAR S V, KIMLINGER T, et al . CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations[J ] . Leukemia, 2005, 19(8): 1466-1470. DOI:10.1038/sj.leu.2403823.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and validation of a prognostic model based on cuproptosis-related genes in patients with multiple myeloma

Influence of targeted inhibition of DNAJC1 gene on apoptosis and proliferation in multiple myeloma cells

Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma: clinical analysis of 53 cases

Silencing NUPR1 down-regulates autophagy and promotes migration and invasion in human multiple myeloma U266 cells

Related Author

ZHAO Li

FENG Youfan

CAO Tingyong

WU Zhenzhen

LI Licheng

KANG Zhongmin

LI Qinshan

LI Mengxing

Related Institution

The First Clinical Medical College， Lanzhou University

Department of Hematology， the Second Hospital & Clinical Medical School， Lanzhou University

Department of Hematology， Gansu Provincial Hospital

Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases， the First Hospital， Lanzhou University

The Laboratory Center， the First Hospital， Lanzhou University

⁰